| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The specific molecular target of Flazin is not explicitly defined in standard pharmacological databases. As a natural β-carboline alkaloid, it may interact with various biological targets, potentially including neurotransmitter receptors or enzymes. However, its primary characterization is as a metabolite and natural product. Further research is needed to elucidate its precise mechanism of action and primary binding targets.
|
|---|---|
| ln Vitro |
Flazin enhanced the TG and free fatty acid profiles and dramatically decreased cellular triglycerides (TG) by 12.0–22.4% as compared to the model group [2]. Flazin efficiently lowers lipid droplet size by 10.0-35.3% and cellular neutral lipid concentration by 17.4-53.9%[2]. With an IC50 of 0.51 mM, flazin inhibits xanthine oxidase[3].
In vitro, Flazin has been shown to modulate lipid metabolism. It enhanced the triglyceride (TG) and free fatty acid profiles in cellular models. Compared to a control model group, Flazin dramatically decreased cellular triglycerides by 12.0–22.4%. Additionally, it efficiently lowered lipid droplet size by 10.0–35.3%. These findings suggest potential activity in lipid regulation pathways, though specific IC50 values are not reported. |
| ln Vivo |
Specific in vivo activity data for Flazin are not available in the provided sources. As a natural product and metabolite, its effects in living organisms have not been extensively characterized. The compound is primarily utilized as a research chemical for in vitro studies to explore its biological activities, particularly its effects on lipid metabolism. Further in vivo studies would be required to assess its pharmacokinetics and pharmacodynamics.
|
| Enzyme Assay |
As Flazin is not a conventional enzyme inhibitor or receptor ligand with a defined cell-free assay, its activity is typically not assessed in such systems. Its properties as a natural product are characterized by its chemical structure and purity. Quality control for research-grade Flazin involves analytical techniques such as High-Performance Liquid Chromatography (HPLC), Nuclear Magnetic Resonance (NMR), and Mass Spectrometry (MS) to confirm identity and purity.
|
| Cell Assay |
In vitro cellular experiments with Flazin typically involve assessing its effects on lipid metabolism in cultured cells. A representative study used a cellular model to evaluate its impact on triglyceride levels and lipid droplet size. Cells were treated with Flazin, and subsequent measurements of cellular triglycerides and lipid droplet morphology were performed. The compound demonstrated a significant decrease in triglycerides (12.0–22.4%) and a reduction in lipid droplet size (10.0–35.3%) compared to the model group.
|
| Animal Protocol |
Specific in vivo animal实验 protocols for Flazin are not described in the available sources. As a research compound with in vitro activity in lipid metabolism, it could potentially be evaluated in animal models of metabolic disease, such as high-fat diet-induced obesity models in mice. In such studies, the compound would be administered to evaluate its effects on serum lipids and hepatic steatosis. However, no such data or protocols are provided.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Flazin are not reported in the available sources. As a natural product used primarily for in vitro research, its absorption, distribution, metabolism, and excretion (ADME) profiles have not been characterized. The compound is a yellow powder with a molecular weight of 308.29. Standard storage conditions for research compounds, such as keeping it in a cool, dry place protected from light, are recommended.
|
| Toxicity/Toxicokinetics |
Toxicity data for Flazin are not provided in the available sources. As a natural product, it may have a favorable safety profile, but no specific toxicological information is available from the references cited. The compound is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
Flazin is a Halman alkaloid and a metabolite. It has been reported that Flazin is found in soybeans, cordyceps, and Javanese brusa, and relevant data are available for reference.
Flazin (CAS: 100041-05-2) is a harmala alkaloid and natural product with a role as a metabolite. It has been identified in various sources including Glycine max, Ophiocordyceps sinensis, and Brucea javanica. The compound is a β-carboline derivative, specifically 1-[5-(hydroxymethyl)furan-2-yl]-9H-pyrido[3,4-b]indole-3-carboxylic acid. It is a yellow powder with a molecular formula of C17H12N2O4. Flazin has demonstrated activity in modulating lipid metabolism in vitro. It is not an approved drug and is strictly for research purposes. |
| Molecular Formula |
C17H12N2O4
|
|---|---|
| Molecular Weight |
308.28818
|
| Exact Mass |
308.08
|
| CAS # |
100041-05-2
|
| PubChem CID |
5377686
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.513g/cm3
|
| Boiling Point |
657.1ºC at 760mmHg
|
| Melting Point |
231 - 233 °C
|
| Flash Point |
351.2ºC
|
| Vapour Pressure |
3.69E-18mmHg at 25°C
|
| Index of Refraction |
1.771
|
| LogP |
3.166
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
460
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OCC1OC(C2C3NC4C(C=3C=C(C(O)=O)N=2)=CC=CC=4)=CC=1
|
| InChi Key |
USBWYUYKHHILLZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H12N2O4/c20-8-9-5-6-14(23-9)16-15-11(7-13(19-16)17(21)22)10-3-1-2-4-12(10)18-15/h1-7,18,20H,8H2,(H,21,22)
|
| Chemical Name |
1-[5-(hydroxymethyl)furan-2-yl]-9H-pyrido[3,4-b]indole-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2437 mL | 16.2185 mL | 32.4370 mL | |
| 5 mM | 0.6487 mL | 3.2437 mL | 6.4874 mL | |
| 10 mM | 0.3244 mL | 1.6218 mL | 3.2437 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
